Amgen Successfully Completes Acquisition of Five Prime Therapeutics
PLEASE READ THE ANNOUNCEMENT
Our Programs
Pipeline
Bemarituzumab
FPT155
FPA157
TIM-3
Clinical Trials
Expanded Access
Publications
Contact